Skip to main content
SpringerLink
Log in

Interchangeability of Biosimilars: Overcoming the Final Hurdles

  • Commentary
  • Published:
Drugs Aims and scope Submit manuscript

A Correction to this article was published on 07 April 2022

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

References

  1. IQVIA. The Impact of Biosimilar Competition in Europe. 2020. Available from https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe. Accessed 12 Oct 2021.

  2. Moors EHM. Challenges for the adoption of future biosimilars. Eur J Hosp Pharm Pract. 2007;2007(13):57–8.

    Google Scholar 

  3. European Medicines Agency and the European Commission. Biosimilars in the EU—Information guide for healthcare professionals. 2017.

  4. Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off–patent biologics and biosimilar markets : it is not only about price! BioDrugs. 2020;34(2):159–70.

    Article  CAS  Google Scholar 

  5. Barbier L, Mbuaki A, Simoens S, Vulto A, Huys I. PNS151 the role of regulatory guidance and information dissemination for biosimilar medicines—the perspective of healthcare professionals and industry. Value Health. 2019;1(22):S786–7.

    Article  Google Scholar 

  6. Cohen HP, McCabe D. The importance of countering biosimilar disparagement and misinformation. BioDrugs. 2020;34(4):407–14.

    Article  Google Scholar 

  7. Barbier L, Ebbers H, Declerck P, Simoens S, Vulto A, Huys I. The efficacy, safety and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–55.

    Article  Google Scholar 

  8. Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Antonia M, et al. Non-pharmacological effects in switching medication : the Nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32(5):397–404.

    Article  Google Scholar 

  9. Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963–7.

    Article  Google Scholar 

  10. Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021. https://doi.org/10.1007/s40265-021-01601-2.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mysler E, Azevedo VF, Danese S, Alvarez D, Noriko I, Ingram B, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021. https://doi.org/10.1007/s40265-021-01610-1.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–7.

    Article  CAS  Google Scholar 

  13. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–6.

    Article  CAS  Google Scholar 

  14. Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M, et al. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83–91.

    Article  CAS  Google Scholar 

  15. Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–34.

    Article  Google Scholar 

  16. Pinheiro LC, Giezen TJ, Wolff-Holz E, Weise M, Laslop A, Hidalgo-Simon A. Identifiability of biologicals: an analysis using the EMA adverse drug reaction database, EudraVigilance. Clin Pharmacol Ther. 2021. https://doi.org/10.1002/cpt.2411.

    Article  Google Scholar 

  17. Tolonen HM, Airaksinen MSA, Ruokoniemi P, Hämeen-anttila K, Shermock KM, Kurki P. Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study. BMJ Open. 2019;9:e032892.

    Article  Google Scholar 

  18. Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: part II—improving biosimilar use in clinical practice. BioDrugs. 2020;34:797–808.

    Article  Google Scholar 

  19. Ben-Horin S, Yavzori M, Benhar I, Ella Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65(7):1132–8.

    Article  CAS  Google Scholar 

  20. Ruiz-Argüello M, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75(9):1693–6.

    Article  Google Scholar 

  21. Fiorino G, Begona Ruiz-Arguello M, Maguregui A, Nagore D, Correale C, Radice S, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(3):601–6.

    Article  Google Scholar 

  22. Goncalves J, Santos M, Acurcio R, Iria I, Gouveia L, Matos Brito P, et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Aliment Pharmacol Ther. 2018;48(5):507–22.

    Article  CAS  Google Scholar 

  23. Pouillon L, Allocca M, Peyrin-Biroulet L. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Aliment Pharmacol Ther. 2018;48(5):574–5.

    Article  CAS  Google Scholar 

  24. Medicines for Europe. The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days. 2020. [cited 2021 Sep 1]. https://www.medicinesforeurope.com/2020/12/16/the-total-clinical-experience-with-biosimilar-medicines-exceeds-2-billion-patient-treatment-days/. Accessed 12 Oct 2021.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Leuven, Belgium

    Liese Barbier & Arnold G. Vulto

  2. Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands

    Arnold G. Vulto

Authors
  1. Liese Barbier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnold G. Vulto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold G. Vulto.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

AGV is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund). AGV is involved in consulting, educational work, and speaking engagements, i.e., AbbVie, Accord, Amgen, Biogen, Effik, Pfizer/Hospira, Fresenius-Kabi, Mundipharma, Roche, Novartis, Sandoz, and Boehringer Ingelheim. LB’s research is supported by the KU Leuven and the MABEL Fund. LB has no commercial or financial relationship that could be perceived as a potential conflict of interest. AGV or LB were not involved in the Kurki or Mysler papers.

Ethics approval

Not applicable

Consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and material

Not applicable

Code availability

Not applicable

Authors’ contributions

AGV and LB wrote, revised, and approved this commentary.

Additional information

The original article has been updated: Due to retrospective open choice cancellation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barbier, L., Vulto, A.G. Interchangeability of Biosimilars: Overcoming the Final Hurdles. Drugs 81, 1897–1903 (2021). https://doi.org/10.1007/s40265-021-01629-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01629-4

Search

Navigation